Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoosier Cancer Research Network
Seagen Inc.
Merck Sharp & Dohme LLC
Alliance for Clinical Trials in Oncology
Fox Chase Cancer Center
Mayo Clinic
Emory University
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Inhibrx Biosciences, Inc
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC
University of Southern California
OncoC4, Inc.
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc